solo para uso en investigación
Cat. No.: S2753
Estructura química
| Dianas relacionadas | EGFR VEGFR FGFR PDGFR Src MEK CSF-1R HER2 FLT3 c-Kit |
|---|---|
| Otros c-Met Inhibidores | Tepotinib (EMD-1214063) Dihexa SGX-523 PHA-665752 Foretinib (GSK1363089, XL880) SU11274 BMS-777607 JNJ-38877605 PF-04217903 Savolitinib (AZD6094) |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| MNK-45 | Kinase assay | ~10 μM | inhibits c-Met phosphorylation and downstream c-Met signaling pathways | |||
| HT29 | Kinase assay | ~10 μM | inhibits c-Met phosphorylation and downstream c-Met signaling pathways | |||
| MDA-MB-231 | Kinase assay | ~10 μM | inhibits c-Met phosphorylation and downstream c-Met signaling pathways | |||
| NCI-H441 | Kinase assay | ~10 μM | inhibits c-Met phosphorylation and downstream c-Met signaling pathways | |||
| SK-MEL-28 | Growth inhibitory assay | 33 μM | IC50>33 μM | |||
| NCI-H661 | Growth inhibitory assay | 33 μM | IC50>33 μM | |||
| NCI-H446 | Growth inhibitory assay | 33 μM | IC50=7 μM | |||
| MDA-MB-231 | Growth inhibitory assay | 33 μM | IC50=0.55 μM | |||
| DLD-1 | Growth inhibitory assay | 33 μM | IC50=0.53 μM | |||
| A549 | Growth inhibitory assay | 33 μM | IC50=0.59 μM | |||
| SK-OV-3 | Growth inhibitory assay | 33 μM | IC50=0.66 μM | |||
| NCI-H460 | Growth inhibitory assay | 33 μM | IC50=0.6 μM | |||
| A375 | Growth inhibitory assay | 33 μM | IC50=0.42 μM | |||
| NCI-H441 | Growth inhibitory assay | 33 μM | IC50=0.3 μM | |||
| HT29 | Growth inhibitory assay | 33 μM | IC50=0.49 μM | |||
| MKN-45 | Growth inhibitory assay | 33 μM | IC50=0.58 μM | |||
| HT29 | Apoptosis assay | ~10 μM | significantly induces apoptosis by 80-90%. | |||
| MKN-45 | Apoptosis assay | ~10 μM | significantly induces apoptosis by 80-90%. | |||
| MDA-MB-231 | Apoptosis assay | ~10 μM | modestly induces apoptosis by 35%. | |||
| MDA-MB-231/TGL | Growth inhibitory assay | ~100 μM | GI50=1.2 μM | |||
| 1833/TGL | Growth inhibitory assay | ~100 μM | GI50=3.7 μM | |||
| EBC1 | Cytotoxic assay | ~10 μM | inhibits the cell growth. | |||
| SNU638 | Cytotoxic assay | ~10 μM | inhibits the cell growth. | |||
| A549 | Cytotoxic assay | ~10 μM | not affect | |||
| H460 | Cytotoxic assay | ~10 μM | not affect | |||
| HCC827 | Cytotoxic assay | ~10 μM | not affect | |||
| A549 | Function assay | 10 μM | disrupts microtubule | |||
| EBC1 | Function assay | 10 μM | disrupts microtubule | |||
| H460 | Function assay | 10 μM | inhibits tubulin polymerization | |||
| K562/VCR | Cytotoxic assay | ~10 μM | shows cytotoxic activity | |||
| CEM/VBL | Cytotoxic assay | ~10 μM | shows cytotoxic activity | |||
| U266 | Cytotoxic assay | ~3 μM | IC50=1.1 μM | |||
| OPM-2 | Cytotoxic assay | ~3 μM | IC50=1.8 μM | |||
| MM.1S | Cytotoxic assay | ~3 μM | IC50=1.6 μM | |||
| MM.1R | Growth inhibitory assay | 3 μM | inhibits cell growth by 49% | |||
| RPMI-8226 | Cytotoxic assay | ~3 μM | IC50=0.9 μM | |||
| ANBL-6 | Cytotoxic assay | 1 μM | induces cell death by more than 50% | |||
| ANLB-6/V10R | Cytotoxic assay | 1 μM | induces cell death by more than 50% | |||
| KAS-6/1 | Cytotoxic assay | 1 μM | induces cell death by more than 50% | |||
| KAS-6/V10R | Cytotoxic assay | 1 μM | induces cell death by more than 50% | |||
| KAS-6/R10R | Cytotoxic assay | 1 μM | induces cell death by more than 50% | |||
| 8226/S | Growth inhibitory assay | 3 μM | inhibits cell growth by 54% | |||
| 8226/LR-5 | Growth inhibitory assay | 3 μM | inhibits cell growth by 54% | |||
| Huh7 | Cytotoxic assay | ~4.8 μM | DMSO | IC50=9.9 nM | ||
| Hep3B | Cytotoxic assay | ~4.8 μM | DMSO | IC50=448.7 nM | ||
| HepG2 | Cytotoxic assay | ~4.8 μM | DMSO | IC50=139.77 nM | ||
| Chang | Cytotoxic assay | ~4.8 μM | DMSO | IC50=448.7 nM | ||
| Huh7 | Function assay | 1.6 μM | DMSO | causes a G2/M cell cycle arrest | ||
| Hep3B | Function assay | 1.6 μM | DMSO | causes a G2/M cell cycle arrest | ||
| HepG2 | Function assay | 1.6 μM | DMSO | causes a G2/M cell cycle arrest | ||
| Chang | Function assay | 1.6 μM | DMSO | causes a G2/M cell cycle arrest | ||
| MHCC97L | Growth inhibitory assay | ~10 μM | DMSO | IC50=315 nM | ||
| MHCC97H | Growth inhibitory assay | ~10 μM | DMSO | IC50=368 nM | ||
| Huh7 | Growth inhibitory assay | ~10 μM | DMSO | IC50=265 nM | ||
| HepG2 | Growth inhibitory assay | ~10 μM | DMSO | IC50=392 nM | ||
| MHCC97L | Function assay | 1 μM | DMSO | induces microtubules depolymerization | ||
| Huh7 | Function assay | 1 μM | DMSO | induces microtubules depolymerization | ||
| MHCC97L | Apoptosis assay | 1 μM | DMSO | induces apoptosis | ||
| Huh7 | Apoptosis assay | 1 μM | DMSO | induces apoptosis | ||
| C3H 10T1/2 mouse fibroblasts | Kinase assay | 25 μM | DMSO | reduces Histone H3 and H4 acetylation levels | ||
| H23 | Growth inhibitory assay | 25 μM | DMSO | significantly inhibits cell growth. | ||
| WM35 | Growth inhibitory assay | 10 μM | DMSO | significantly inhibits cell growth. | ||
| NIH 3T3 | Growth inhibitory assay | 10 μM | DMSO | does not have a significant inhibitory effect | ||
| H838 | Growth inhibitory assay | 10 μM | DMSO | does not have a significant inhibitory effect | ||
| H1395 | Growth inhibitory assay | 10 μM | DMSO | does not have a significant inhibitory effect | ||
| Quiescent S2 | Kinase assay | 30 μM | DMSO | completely abrogates TSA-induced hyperacetylation of H3K4me3 histones | ||
| PC3 | Apoptosis assay | 20 μM | DMSO | induces apoptosis | ||
| Du145 | Apoptosis assay | 20 μM | DMSO | induces apoptosis | ||
| LNCaP | Apoptosis assay | 20 μM | DMSO | induces apoptosis | ||
| LAPC-4 | Apoptosis assay | 20 μM | DMSO | induces apoptosis | ||
| LNCaP | Function assay | 20 μM | DMSO | decreases PSA secretion and p65 expression levels | ||
| LAPC-4 | Function assay | 20 μM | DMSO | decreases PSA secretion and p65 expression levels | ||
| Kasumi-1 | Growth inhibitory assay | ~50 μM | DMSO | inhibits cell proliferation | ||
| SKNO-1 | Growth inhibitory assay | ~50 μM | DMSO | inhibits cell proliferation | ||
| Kasumi-1 | Kinase assay | ~10 μM | DMSO | reduces expression of acetylated histone H3, c-kit and bcl-2 | ||
| SKNO-1 | Kinase assay | ~10 μM | DMSO | reduces expression of acetylated histone H3, c-kit and bcl-2 | ||
| A549 | Function assay | 10 μM | DMSO | enhances mitotic catastrophe | ||
| NRK-52E | Function assay | 10 μM | DMSO | inhibits Ang II-induced STAT3 nuclear translocation and the expression of TGF-β1, collagen IV and fibronectin | ||
| PC12 | Growth inhibitory assay | ~12.5 μM | DMSO | prevents TSA-induced neurite formation | ||
| HPMCs | Function assay | reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells | ||||
| A549 | Function assay | ~50 μM | DMSO | affects the viral life cycle and host response | ||
| RAW264.7 | Function assay | ~30 μM | DMSO | reduces pro-inflammatory gene expression | ||
| MEMM | Kinase assay | 15 µM | DMSO | decreases acetylation of histone H3 | ||
| MEMM | Growth inhibitory assay | ~20 µM | DMSO | inhibits cell proliferation | ||
| MEMM | Apoptosis assay | 15 µM | DMSO | induces the presence of the apoptosis protein, cleaved Caspase-3 | ||
| T47D | Growth inhibitory assay | 10 μM | DMSO | IC50=72 nM | ||
| ZR-75-1 | Growth inhibitory assay | 10 μM | DMSO | IC50=79 nM | ||
| BT474 | Growth inhibitory assay | 10 μM | DMSO | IC50=86 nM | ||
| HCC1954 | Growth inhibitory assay | 10 μM | DMSO | IC50=119 nM | ||
| MDA-MB-453 | Growth inhibitory assay | 10 μM | DMSO | IC50=975 nM | ||
| MDA-MB-468 | Growth inhibitory assay | 10 μM | DMSO | IC50=3208 nM | ||
| SkBr3 | Growth inhibitory assay | 10 μM | DMSO | IC50>10,000 nM | ||
| MDA-MB-231 | Growth inhibitory assay | 10 μM | DMSO | IC50>10,000 nM | ||
| HCT116 | Growth inhibitory assay | 10 μM | DMSO | IC50=5836 nM | ||
| HT29 | Growth inhibitory assay | 10 μM | DMSO | IC50>10,000 nM | ||
| HFF | Growth inhibitory assay | 10 μM | DMSO | IC50=7615 nM | ||
| HN5 | Growth inhibitory assay | 10 μM | DMSO | IC50>10,000 nM | ||
| 786-0 | Growth inhibitory assay | 10 μM | DMSO | IC50=4009 nM | ||
| H157 | Growth inhibitory assay | 10 μM | DMSO | IC50=2642 nM | ||
| NCI-H460 | Growth inhibitory assay | 10 μM | DMSO | IC50>2,500 nM | ||
| SKOV-3 | Growth inhibitory assay | 10 μM | DMSO | IC50=2126 nM | ||
| OVCAR-3 | Growth inhibitory assay | 10 μM | DMSO | IC50=2918 nM | ||
| BXPC3 | Growth inhibitory assay | 10 μM | DMSO | IC50=3141 nM | ||
| MiaPaCa | Growth inhibitory assay | 10 μM | DMSO | IC50=5433 nM | ||
| PANC-1 | Growth inhibitory assay | 10 μM | DMSO | IC50=8681 nM | ||
| LNCaP | Growth inhibitory assay | 10 μM | DMSO | IC50=147 nM | ||
| DU145 | Growth inhibitory assay | 10 μM | DMSO | IC50=3812 nM | ||
| PC3 | Growth inhibitory assay | 10 μM | DMSO | IC50>10,000 nM | ||
| BT474 | Kinase assay | 10 μM | DMSO | inhibits pGSK3β with IC50 of 160 nM | ||
| 786-0 | Kinase assay | 10 μM | DMSO | inhibits pGSK3β with IC50 of 150 nM | ||
| LNCaP | Kinase assay | 10 μM | DMSO | inhibits pGSK3β with IC50 of 43 nM | ||
| PC3 | Kinase assay | 10 μM | DMSO | inhibits pGSK3β with IC50 of 49 nM | ||
| KARPAS-231 | Growth inhibitory assay | 10 μM | DMSO | EC50=41 nM | ||
| CCRFSB | Growth inhibitory assay | 10 μM | DMSO | EC50=155 nM | ||
| SUP B15 | Growth inhibitory assay | 10 μM | DMSO | EC50=197 nM | ||
| SD-1 | Growth inhibitory assay | 10 μM | DMSO | EC50=320 nM | ||
| RS4;11 | Growth inhibitory assay | 10 μM | DMSO | EC50=654 nM | ||
| MN-60 | Growth inhibitory assay | 10 μM | DMSO | EC50=3602 nM | ||
| Tanoue | Growth inhibitory assay | 10 μM | DMSO | EC50=4517 nM | ||
| RCH-ACV | Growth inhibitory assay | 10 μM | DMSO | EC50=152 nM | ||
| SEM | Growth inhibitory assay | 10 μM | DMSO | EC50=202 nM | ||
| KASUMI-2 | Growth inhibitory assay | 10 μM | DMSO | EC50=225 nM | ||
| REH | Growth inhibitory assay | 10 μM | DMSO | EC50=288 nM | ||
| 697 | Growth inhibitory assay | 10 μM | DMSO | EC50=338 nM | ||
| NALM-6 | Growth inhibitory assay | 10 μM | DMSO | EC50=421 nM | ||
| MHH-CALL–3 | Growth inhibitory assay | 10 μM | DMSO | EC50=812 nM | ||
| MHH-CALL–2 | Growth inhibitory assay | 10 μM | DMSO | EC50=2114 nM | ||
| J.GAMMA-1 | Growth inhibitory assay | 10 μM | DMSO | EC50=65 nM | ||
| JR45.01 | Growth inhibitory assay | 10 μM | DMSO | EC50=68 nM | ||
| A3 | Growth inhibitory assay | 10 μM | DMSO | EC50=69 nM | ||
| I 2.1 | Growth inhibitory assay | 10 μM | DMSO | EC50=73 nM | ||
| MOLT-3 | Growth inhibitory assay | 10 μM | DMSO | EC50=74 nM | ||
| P116 | Growth inhibitory assay | 10 μM | DMSO | EC50=78 nM | ||
| J.Cam1.6 | Growth inhibitory assay | 10 μM | DMSO | EC50=79 nM | ||
| I 9.2 | Growth inhibitory assay | 10 μM | DMSO | EC50=80 nM | ||
| LOUCY | Growth inhibitory assay | 10 μM | DMSO | EC50=117 nM | ||
| J.RT3-T3.5 | Growth inhibitory assay | 10 μM | DMSO | EC50=123 nM | ||
| 800000 | Growth inhibitory assay | 10 μM | DMSO | EC50=163 nM | ||
| Jurkat | Growth inhibitory assay | 10 μM | DMSO | EC50=225 nM | ||
| MOLT-4 | Growth inhibitory assay | 10 μM | DMSO | EC50=232 nM | ||
| Molt-16 | Growth inhibitory assay | 10 μM | DMSO | EC50=241 nM | ||
| CEM/C3 | Growth inhibitory assay | 10 μM | DMSO | EC50=257 nM | ||
| CEM/C2 | Growth inhibitory assay | 10 μM | DMSO | EC50=271 nM | ||
| CCRFCEM | Growth inhibitory assay | 10 μM | DMSO | EC50=327 nM | ||
| CEM/C1 | Growth inhibitory assay | 10 μM | DMSO | EC50=382 nM | ||
| SUPTI[VB] | Growth inhibitory assay | 10 μM | DMSO | EC50=619 nM | ||
| CCRF–HSB-2 | Growth inhibitory assay | 10 μM | DMSO | EC50=2117 nM | ||
| I 2.1 | Apoptosis assay | 10 μM | DMSO | induces apoptosis | ||
| I 9.2 | Apoptosis assay | 10 μM | DMSO | induces apoptosis | ||
| A3 | Apoptosis assay | 10 μM | DMSO | induces apoptosis | ||
| RD | Growth inhibitory assay | 10 μM | IC50>10 μM | |||
| Rh41 | Growth inhibitory assay | 10 μM | IC50=33.8 nM | |||
| Rh18 | Growth inhibitory assay | 10 μM | IC50=303 nM | |||
| Rh30 | Growth inhibitory assay | 10 μM | IC50=4.81 μM | |||
| BT-12 | Growth inhibitory assay | 10 μM | IC50>10 μM | |||
| CHLA-266 | Growth inhibitory assay | 10 μM | IC50=1.22 μM | |||
| TC-71 | Growth inhibitory assay | 10 μM | IC50=2.52 μM | |||
| CHLA-9 | Growth inhibitory assay | 10 μM | IC50=591 nM | |||
| CHLA-10 | Growth inhibitory assay | 10 μM | IC50=102 nM | |||
| CHLA-258 | Growth inhibitory assay | 10 μM | IC50=1.05 μM | |||
| GBM2 | Growth inhibitory assay | 10 μM | IC50=9.15 μM | |||
| NB-1643 | Growth inhibitory assay | 10 μM | IC50=5.4 μM | |||
| NB-Ebc1 | Growth inhibitory assay | 10 μM | IC50>10 μM | |||
| CHLA-90 | Growth inhibitory assay | 10 μM | IC50>10 μM | |||
| CHLA-136 | Growth inhibitory assay | 10 μM | IC50>10 μM | |||
| NALM-6 | Growth inhibitory assay | 10 μM | IC50=265 nM | |||
| COG-LL-317 | Growth inhibitory assay | 10 μM | IC50=6.49 nM | |||
| RS4;11 | Growth inhibitory assay | 10 μM | IC50=147 nM | |||
| MOLT-4 | Growth inhibitory assay | 10 μM | IC50=40 nM | |||
| CCRF-CEM | Growth inhibitory assay | 10 μM | IC50=268 nM | |||
| Kasumi-1 | Growth inhibitory assay | 10 μM | IC50=107 nM | |||
| Karpas-299 | Growth inhibitory assay | 10 μM | IC50=2.93 μM | |||
| Ramos-RA1 | Growth inhibitory assay | 10 μM | IC50=7.35 μM | |||
| H1299 | Kinase assay | 10 μM | inhibits IKBKE-induced Akt Activation | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 369.42 | Fórmula | C23H19N3O2 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 905854-02-6 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | ARQ 197 | Smiles | C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65 | ||
|
In vitro |
DMSO
: 73 mg/mL
(197.6 mM)
Ethanol : 35 mg/mL Water : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Características |
The first selective c-Met inhibitor to be advanced into human clinical trials.
|
|---|---|
| Targets/IC50/Ki |
c-Met
(Cell-free assay) 0.355 μM(Ki)
|
| In vitro |
ARQ-197 has been shown to prevent HGF/c-met induced cellular responses in vitro. This compound possesses antitumor activity; inhibiting proliferation of A549, DBTRG and NCI-H441 cells with IC50 of 0.38, 0.45, 0.29 μM. Treatment with this agent results in a decrease in phosphorylation of the MAPK signaling cascade and prevention of invasion and migration. In addition, ectopic expression of c-Met in NCI-H661, a cell line having no endogenous expression of c-Met, causes it to acquire an invasive phenotype that is also suppressed by this chemical. Although the addition of increasing concentrations of this inhibitor does not significantly affect the Km of ATP, exposure of c-Met to 0.5 μM of this substance decreased the Vmax of c-Met by approximately 3-fold. The ability of this molecule to decrease the Vmax without affecting the Km of ATP confirmed that it inhibits c-Met through a non–ATP-competitive mechanism and may therefore account for its high degree of kinase selectivity. It prevents human recombinant c-Met with a calculated inhibitory constant Ki of approximately 355 nM. Although the highest concentration of ATP used is 200 μM, the potency of this compound against c-Met is not reduced by using concentrations of ATP up to 1 mM. It blocks c-Met phosphorylation and downstream c-Met signaling pathways. This chemical suppresses constitutive and ligand-mediated c-Met autophosphorylation and, by extension, c-Met activity, in turn leading to the inhibition of downstream c-Met effectors. Its induction of caspase-dependent apoptosis is increased in c-Met–expressing human cancer cells including HT29, MKN-45, and MDA-MB-231 cells. |
| Ensayo de quinasa |
Ensayo de quinasa in vitro SDS-PAGE de c-Met
|
|
La proteína c-Met recombinante (100 ng) se preincuba con concentraciones crecientes de este compuesto durante 30 minutos a temperatura ambiente. Después de la preincubación, se añaden 100 μM de sustrato poli-Glu-Tyr y varias concentraciones de ATP que contienen 5 μCi de [γ-32P]ATP a la mezcla de reacción. La reacción se incuba durante 5 minutos a temperatura ambiente y luego se detiene con la adición de 5 μL de gel de SDS-poliacrilamida, tampón de muestra reductor. Las muestras se cargan luego en un gel de acrilamida al 7,5% y se realiza una SDS-PAGE. Los sustratos poli-Glu-Tyr fosforilados se visualizan finalmente mediante autorradiografía. La actividad de c-Met se cuantifica por densitometría.
|
|
| In vivo |
All three xenograft models treated with Tivantinib display reductions in tumor growth: 66% in the HT29 model, 45% in the MKN-45 model, and 79% in the MDA-MB-231 model. In these xenograft studies, no significant body weight changes following oral administration of this compound at 200 mg/kg are observed. Pharmacodynamically, the phosphorylation of c-Met in human colon xenograft tumors (HT29) is strongly inhibited by this chemical, as assessed by a dramatic reduction of c-Met autophosphorylation 24 hours after a single oral dose of 200 mg/kg of this agent. This same dosage in mice exhibits that tumor xenografts are exposed to sustained plasma levels of the compound, consistent with the observed pharmacodynamic inhibition of c-Met phosphorylation and inhibition of proliferation of c-Met harboring cancer cell lines. Plasma levels of the agent 10 hours after dosing are determined to be 1.3 μM, more than 3-fold above the biochemical inhibitory constant of this substance for c-Met. Therefore, it is able to suppress its target in vivo in the xenografted human tumor tissue. In conclusion, this inhibitor blocks the growth of c-Met-dependent xenografted human tumors. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | cMET / p-cMET / p-AKT / p-ERK / p-rpS6 |
|
23022995 |
| Growth inhibition assay | Cell viability |
|
23598276 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT02150733 | Completed | Hepatic Impairment|Solid Tumor|Cancer |
Daiichi Sankyo|Medpace Inc. |
April 2014 | Phase 1 |
| NCT01892527 | Completed | Colorectal Cancer Metastatic|C-met Overexpression |
Armando Santoro MD|Istituto Clinico Humanitas |
March 2013 | Phase 2 |
| NCT02049060 | Completed | Malignant Pleural Mesothelioma|Nonsquamous Nonsmall Cell Neoplasm of Lung |
Armando Santoro MD|Istituto Clinico Humanitas |
January 2013 | Phase 1|Phase 2 |
| NCT01755767 | Completed | Hepatocellular Carcinoma |
Daiichi Sankyo|ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA) |
December 27 2012 | Phase 3 |
Pregunta 1:
Are there any other solutions (apart from DMSO) I can dissolve it for in vivo experiment?
Respuesta:
S2753 This compound (ARQ 197) can be dissolved in 1% methylcellulose at 15 mg/ml as a suspension.